The invention relates to an ethylene cationic polymer comprising at least one primary, secondary or tertiary protonable amine function which is at least partially neutralized by a polymer organic acid neutralizing agent which contains at least one carboxylic, sulphonic and/or phosphonic acid function. Said invention also relates to a cosmetic or pharmaceutical composition comprising said neutralized polymer in a physiologically acceptable medium, in particular, cosmetically or pharmaceutically acceptable medium. A method for cosmetically treating keratinic materials, such as a body of face skin, nails, hairs, eyebrows and/or eyelashes, consisting in applying the inventive cosmetic composition to said keratinic materials is also disclosed.

Compositions and methods for making a composition comprising a polymer and one or more chelators covalently coupled to polymer, wherein the one or more chelators has a benzene ring with more than one hydroxyl group at any position that is free, or a derivative of the chelator, or a salt of the chelator and methods of use.

Processes for inhibiting scale produced during wet process phosphoric acid production by adding a scale-inhibiting amount of a reagent having a primary amine-containing polymer, or salt thereof, to one or more stages of a wet process phosphoric acid production stream are provided herein, wherein the primary amine-containing polymer includes an A mer according to Formula (I): ##STR00001## where R is H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, halide, or carboxyl; R.sup.1 is H, C.sub.1-C.sub.6 alkyl, or C.sub.2-C.sub.6 alkenyl; R.sup.2 is H or an A mer according to Formula (I) as herein defined; R.sup.3 is chosen from a direct bond or a C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, or a C.sub.6-C.sub.12 aryl group; and n is an integer chosen to provide a weight average molecular weight of the primary amine-containing polymer of at least 300 Daltons, and
wherein the percentage of primary amines in the polymer is from 30 mole % to 100 mole % based on the total percentage of mer units in the polymer.

Processes for inhibiting scale produced during wet process phosphoric acid production by adding a scale-inhibiting amount of a reagent having a primary amine-containing polymer, or salt thereof, to one or more stages of a wet process phosphoric acid production stream are provided herein, wherein the primary amine-containing polymer includes an A mer according to Formula (I): ##STR00001## where R is H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, halide, or carboxyl; R.sup.1 is H, C.sub.1-C.sub.6 alkyl, or C.sub.2-C.sub.6 alkenyl; R.sup.2 is H or an A mer according to Formula (I) as herein defined; R.sup.3 is chosen from a direct bond or a C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, or a C.sub.6-C.sub.12 aryl group; and n is an integer chosen to provide a weight average molecular weight of the primary amine-containing polymer of at least 300 Daltons, and
wherein the percentage of primary amines in the polymer is from 30 mole % to 100 mole % based on the total percentage of mer units in the polymer.

The present disclosure is directed to a continuous process for preparing cellulose reactive adducts of polyvinylamide.

The present disclosure is directed to a continuous process for preparing cellulose reactive adducts of polyvinylamide.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Cross-linked cyclopolymeric resins from N,N-diallyl quaternary ammonium monomers and tetrallylpiperazinium cross-linking monomer or salts, solvates, tautomers or stereoisomers as adsorbent materials for the removal of heavy metals from aqueous solution. A process for producing the cross-linked cyclopolymeric resins by Butler cyclocopolymerization of the monomers with a free radical initiator. The cross linked cyclopolymeric resins are polyzwitterionic or polyzwitterionic and dianionic and feature repeating units with multiple chelating centers that heavy metal ions can bind to. In addition, a method for removing heavy metals from aqueous solution via contacting and treatment with the cross-linked cyclopolymeric resins.